The presence of adverse reactions, such as skin reactions or diarrhea, can be explained by the roles of transporters in the oral absorption and elimination pathways of gefitinib, as ABCG2 is highly expressed in the intestine and liver [47]. This evidence concerns the gene ABCG2 and skin reaction.